AZTherapies
Boston
About AZTherapies
AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population. Advancing a growing pipeline to treat patients with few therapeutic options, the Company’s lead candidate, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of the disease. The Phase 3 COGNITE trial in early Alzheimer’s disease is fully enrolled and expected to complete in late 2020. Following the lead program, AZTherapies is advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), and other indications. AZTherapies is a private company founded in 2011 and headquartered in Boston, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $99.8M
- Last round: Series Unknown (Sep 2020)
- Website: aztherapies.com
- Phone: (617) 318-3411
Industries & Categories
Biopharma, Biotechnology, Health Care, Neuroscience, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/aztherapies-29296 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.